Neogen Corp. Stock
Neogen Corp. Stock
A very strong showing by Neogen Corp. today, with an increase of €0.25 (4.130%) compared to yesterday's price.
Our community is currently high on Neogen Corp. with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 11 € shows a very positive potential of 74.6% compared to the current price of 6.3 € for Neogen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Neogen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Neogen Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Neogen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Neogen Corp. | 4.130% | 0.833% | 9.009% | -46.460% | -49.583% | - | - |
| Icu Medical Inc. | 0.000% | 1.639% | 5.983% | -16.779% | -15.646% | -15.646% | -25.749% |
| Bio-Rad Labs Inc. A | 0.310% | -4.716% | -2.173% | -20.286% | -18.306% | -33.420% | -46.318% |
| Haemonetics Corp. | -5.590% | -5.517% | 6.202% | - | - | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
NEOGEN CORP's current financial position shows significant challenges. Key findings include: - Revenue decline from $228.8 million to $221.0 million (year-over-year) - Net loss of $10.957 million compared to a loss of $2.022 million in the previous year - Significant asset impairment charges of $470.832 million - Cash balance decreased from $170.6 million to $127.7 million
The overall financial trend is negative, driven by declining revenue, increasing losses, and significant impairment charges.
These factors highlight both the challenges the company faces in terms of profitability and growth, as well as potential areas for improvement in financial management.
Comments
Neogen (NASDAQ:NEOG) was upgraded by analysts at CJS Securities from a "market perform" rating to an "outperform" rating.
Show more
Ratings data for NEOG provided by MarketBeat
Neogen Corporation (NASDAQ: NEOG) had its price target lowered by analysts at Guggenheim from $13.00 to $10.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NEOG provided by MarketBeat
Neogen Co. (NASDAQ: NEOG) had its price target lowered by analysts at Guggenheim from $15.00 to $13.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NEOG provided by MarketBeat